Article

Hyposensitivity to the amnesic effects of scopolamine or amyloid beta(25-35) peptide in heterozygous acetylcholinesterase knockout (AChE(+/-)) mice.

INSERM U. 710, Montpellier, France.
Chemico-Biological Interactions (Impact Factor: 2.97). 05/2008; 175(1-3):131-4. DOI: 10.1016/j.cbi.2008.04.001
Source: PubMed

ABSTRACT We examined the sensitivity of AChE(+/-) mice to the amnesic effects of scopolamine and amyloid beta peptide. AChE(+/-) and AChE(+/+) littermates, tested at 5-9 weeks of age, failed to show any difference in locomotion, exploration and anxiety in the open-field test, or in-place learning in the water-maze. However, when treated with the muscarinic receptor antagonist scopolamine (0.5, 5mg/kg s.c.) 20 min before each water-maze training session, learning impairments were observed at both doses in AChE(+/+) mice, but only at the highest dose in AChE(+/-) mice. The central injection of Abeta(25-35) peptide (9 nmol) induced learning deficits only in AChE(+/+) but not in AChE(+/-) mice. Therefore, the hyper-activity of cholinergic systems in AChE(+/-) mice did not result in increased memory abilities, but prevented the deleterious effects of muscarinic blockade or amyloid toxicity.

0 Bookmarks
 · 
100 Views
  • Internal Medicine News 01/2010; 43(15):22-22.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Decrease in the expression or activity of acetylcholinesterase (AChE) enzymatic activity results in increased cholinergic tonus in the brain and periphery, with concomitant regulations of nicotinic and muscarinic receptors expression. We generated AChE knockout mice and characterized the behavioral phenotype of heterozygous animals, focusing on learning and memory functions. Male and female, AChE+/− and AChE+/+ littermate controls (129sv strain) were tested at 5–9 weeks of age. AChE activity was significantly decreased in the hippocampus and cortex of AChE+/− mice, but butyrylcholinesterase activity was preserved. AChE+/− mice failed to show any difference in terms of locomotion, exploration and anxiety parameters in the open-field test. Animals were then tested for place learning in the water-maze. They were trained using a ‘sustained acquisition’ protocol (3 swim trials per day) or a ‘mild acquisition’ protocol (2 swim trials per day) to locate an invisible platform in fixed position (reference memory procedure). Then, during 3 days, they were trained to locate the platform in a variable position (working memory procedure). Learning profiles and probe test performances were similar for AChE+/− and AChE+/+ mice. Mice were then treated with the muscarinic receptor antagonist scopolamine (0.5, 5 mg/kg) 20 min before each training session. Scopolamine impaired learning at both doses in AChE+/+ mice, but only at the highest dose in AChE+/− mice. Moreover, the intracerebroventricular injection of amyloid-β25–35 peptide, 9 nmol, 7 days before water-maze acquisition, failed to induce learning deficits in AChE+/− mice, but impaired learning in AChE+/+ controls. The peptide failed to be toxic in forebrain structures of AChE+/− mice, since an increase in lipid peroxidation levels was measured in the hippocampus of AChE+/+ but not AChE+/− mice. We conclude that the increase in cholinergic tonus observed in AChE+/− mice did not result in increased memory functions but allowed a significant prevention of the deleterious effects of muscarinic blockade or amyloid toxicity.
    Behavioural brain research 09/2009; · 3.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We have previously identified presenilin-1 (PS1), the active component of the γ-secretase complex, as an interacting protein of the amyloid-associated enzyme acetylcholinesterase (AChE). In this study, we have explored the consequences of AChE-PS1 interactions. Treatment of SH-SY5Y cells with the AChE-inhibitor tacrine decreased PS1 levels, in parallel with increase in the secretion of amyloid precursor protein APPα, whereas the cholinergic agonist carbachol had no effect on PS1. AChE knockdown with siRNA also decreased PS1 levels, while AChE overexpression exerted opposing effect. AChE-deficient also had decreased PS1. Mice administered with tacrine or donepezil displayed lower levels of brain PS1. However, sustained AChE inhibition failed to exert long-term effect on PS1. This limited duration of response may be due to AChE upregulation caused by chronic inhibition. Finally, we exposed SH-SY5Y cells to β-amyloid (Aβ)42 which triggered elevation of both AChE and PS1 levels. The Aβ42-induced PS1 increase was abolished by siRNA AChE pretreatment, suggesting that AChE may participate in the pathological feedback loop between PS1 and Aβ. Our results provide insight into AChE-amyloid interrelationships.
    Neurobiology of aging 05/2011; 33(3):627.e27-37. · 5.94 Impact Factor

Full-text (2 Sources)

Download
49 Downloads
Available from
Jun 5, 2014